Recent contributions for the identification and screening of Lynch syndrome;Contributions récentes pour l'identification et le dépistage du syndrome de Lynch

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 2, 2007, Pages 136-140

  Olschwang, Sylviane ^a   Paraf, François ^b   Laurent Puig, Pierre ^c   Wang, Qing ^d   Lecuru, Fabrice ^c   Hamelin, Richard ^e   Fléjou, Jean François ^f   Frebourg, Thierry ^g  

^a INSTITUT PAOLI CALMETTES   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSERM   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICROSATELLITE DNA; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN SERINE THREONINE KINASE;

ALLELE; CANCER LOCALIZATION; CARCINOGENESIS; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; IMMUNOHISTOCHEMISTRY; METHYLATION; REVIEW; SOMATIC MUTATION; TUMOR GENE;

EID: 33947186423     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)89343-2     Document Type: Review

References (30)

1. Olschwang S, Eisinger F. Prédisposition héréditaire aux cancers: côlon, rectum, utérus. Collection Pathologie Science. Paris: John Libbey Eurotext, 2005.
2. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 2004;20:251-7.
3. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
5. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63:5209-12.
6. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
7. Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 2005;104:952-61.
8. Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004;39:138-42.
9. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41:664-8.
10. Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005;24:3995-8.
11. de Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MG, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:972-80.
12. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005;4:255-65.
13. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005;23:6524-32.
14. Mangold E, Pagenstecher C, Friedl W, Fischer HP, Merkelbach-Bruse S, Ohlendorf M, et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 2005;207:385-95.
15. Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q, et al. Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet 2004;41:18-20.
16. Grabowski M, Mueller-Koch Y, Grasbon-Frodl E, Koehler U, Keller G, Vogelsang H, et al. Deletions account for 17 % of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families. Genet Test 2005;9:138-46.
17. Kariola R, Hampel H, Frankel WL, Raevaara TE, de la CA, Nystrom-Lahti M. MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 2004;91:1287-92.
18. Nakagawa H, Lockman JC, Frankel WL, Hampel H, Steenblock K, Burgart LJ, et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004;64:4721-7.
19. Miyaki M, Nishio J, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, et al. Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Oncogene 1997;15:2877-81.
20. De Rosa M, Fasano C, Panariello L, Scarano MI, Belli G, Iannelli A, et al. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene 2000;19:1719-23.
21. Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. Cafe-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001;1:101-5.
22. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004;74:954-64.
23. Agostini M, Tibiletti MG, Lucci-Cordisco E, Chiaravalli A, Morreau H, Furlan D, et al. Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol 2005;100:1886-91.
24. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005;42:491-6.
25. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005;331:1047.
26. Lecomte T, Cellier C, Meatchi T, Barbier JP, Cugnenc PH, Jian R, et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005;3:897-902.
27. Hurlstone DP, Karajeh M, Cross SS, McAlindon ME, Brown S, Hunter MD, et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective "back-to-back" endoscopic study. Am J Gastroenterol 2005;100:2167-73.
28. Olschwang S, Laurent-Puig P, Eisinger F, Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut 2005;54:169.
29. Vasen HF, de Vos Tot Nederveen Cappel WH. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut 2005;54:1501-2.
30. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-9.